Temporal trajectory of biofluid markers in Parkinson’s disease

Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer’s disease

(2020) Min Seok Baek et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease

(2020) David J. Irwin et al.   ANNALS OF NEUROLOGY

Serum NFL discriminates Parkinson disease from atypical parkinsonisms

(2019) Tainá M. Marques et al.   NEUROLOGY

Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson’s disease

(2019) Hidetomo Murakami et al.   BMC Neurology

Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease

(2019) Brit Mollenhauer et al.   MOVEMENT DISORDERS

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology

(2019) Claire Bridel et al.   JAMA Neurology

Blood NfL

(2019) Chin-Hsien Lin et al.   NEUROLOGY

CSF or serum neurofilament light added to α‐Synuclein panel discriminates Parkinson's from controls

(2019) Linda P. Oosterveld et al.   MOVEMENT DISORDERS

Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology

(2019) Fares Bassil et al.   NEURON

Fibre-specific white matter reductions in Alzheimer’s disease and mild cognitive impairment

(2018) Remika Mito et al.   BRAIN

CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders

(2018) David J. Irwin et al.   NEUROLOGY

Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease

(2018) Marthe Gurine Førland et al.   PARKINSONISM & RELATED DISORDERS

Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features

(2017) Jennifer G. Goldman et al.   MOVEMENT DISORDERS

Cognitive decline in Parkinson disease

(2017) Dag Aarsland et al.   Nature Reviews Neurology

Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample

(2017) Renaud La Joie et al.   NEUROLOGY

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls

(2017) Brit Mollenhauer et al.   NEUROLOGY

Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer’s Disease

(2017) Ina S. Almdahl et al.   Frontiers in Aging Neuroscience

Microstructural white matter alterations in preclinical Alzheimer’s disease detected using free water elimination diffusion tensor imaging

(2017) Andrew R. Hoy et al.   PLoS One

CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study

(2016) Ju-Hee Kang et al.   ACTA NEUROPATHOLOGICA

Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis

(2016) Lucilla Parnetti et al.   Biomarkers in Medicine

Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson’s Disease1

(2016) Mariateresa Buongiorno et al.   JOURNAL OF ALZHEIMERS DISEASE

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

(2016) Nour K. Majbour et al.   Molecular Neurodegeneration

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease

(2016) Sara Hall et al.   MOVEMENT DISORDERS

Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression

(2016) Nour K. Majbour et al.   MOVEMENT DISORDERS

White matter integrity and cognitive dysfunction: Radiological and neuropsychological correlations

(2015) Hidekazu Tomimoto   Geriatrics & Gerontology International

Biomarkers of cognitive decline in Parkinson's disease

(2015) Chin-Hsien Lin et al.   PARKINSONISM & RELATED DISORDERS

Cerebrospinal Fluid α-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort

(2014) Tessandra Stewart et al.   AMERICAN JOURNAL OF PATHOLOGY

CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival

(2014) T. Skillback et al.   NEUROLOGY

CSF biomarkers and clinical progression of Parkinson disease

(2014) S. Hall et al.   NEUROLOGY

Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons

(2013) Jing L. Guo et al.   CELL

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

(2013) David J. Irwin et al.   NATURE REVIEWS NEUROSCIENCE

Axon degeneration is key component of neuronal death in amyloid-β toxicity

(2013) Wilson M. Alobuia et al.   NEUROCHEMISTRY INTERNATIONAL

Brain  -amyloid load approaches a plateau

(2013) C. R. Jack et al.   NEUROLOGY

Neuropathologic substrates of Parkinson disease dementia

(2012) David J. Irwin et al.   ANNALS OF NEUROLOGY

Lentivirus Mediated Delivery of Neurosin Promotes Clearance of Wild-type α-Synuclein and Reduces the Pathology in an α-Synuclein Model of LBD

(2012) Brian Spencer et al.   MOLECULAR THERAPY

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

(2011) Brit Mollenhauer et al.   LANCET NEUROLOGY

The MoCA: Well-suited screen for cognitive impairment in Parkinson disease

(2010) J. C. Dalrymple-Alford et al.   NEUROLOGY

CSF amyloid   1-42 predicts cognitive decline in Parkinson disease

(2010) A. Siderowf et al.   NEUROLOGY

α-Synuclein contributes to GSK-3β-catalyzed Tau phosphorylation in Parkinson’s disease models

(2009) Tetyana Duka et al.   FASEB JOURNAL

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease

(2009) Yaroslau Compta et al.   MOVEMENT DISORDERS

Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson’s disease patients

(2008) Tammaryn Lashley et al.   ACTA NEUROPATHOLOGICA